FDA OKs Therapy for Rare Genetic Enzyme Disorder FDA OKs Therapy for Rare Genetic Enzyme Disorder

Vestronidase alfa-vjbk (Mepsevii) is the first FDA-approved treatment for children and adults with mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news